1. Home
  2. GDL vs CING Comparison

GDL vs CING Comparison

Compare GDL & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo GDL Fund The of Beneficial Interest

GDL

GDL Fund The of Beneficial Interest

SELL

Current Price

$8.32

Market Cap

94.4M

Sector

Finance

ML Signal

SELL

CING

Cingulate Inc.

HOLD

Current Price

$8.10

Market Cap

93.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GDL
CING
Founded
2006
2012
Country
United States
United States
Employees
N/A
13
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
94.4M
93.1M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
GDL
CING
Price
$8.32
$8.10
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$37.00
AVG Volume (30 Days)
9.3K
519.2K
Earning Date
01-01-0001
03-18-2026
Dividend Yield
6.02%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.71
$3.20
52 Week High
$8.67
$11.89

Technical Indicators

Market Signals
Indicator
GDL
CING
Relative Strength Index (RSI) 34.17 53.20
Support Level $8.22 $3.62
Resistance Level $8.45 N/A
Average True Range (ATR) 0.06 0.95
MACD -0.02 0.28
Stochastic Oscillator 0.00 36.20

Price Performance

Historical Comparison
GDL
CING

About GDL GDL Fund The of Beneficial Interest

GDL Fund is a diversified closed-end management investment company. Its primary investment objective is to achieve absolute returns in various market conditions without excessive risk of capital. The fund seeks to achieve its objective by investing in merger arbitrage transactions and, to a lesser extent, in corporate reorganizations involving stubs, spin-offs, and liquidations.

About CING Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.

Share on Social Networks: